曲美他嗪在冠心病合并心力衰竭治疗中的应用价值探究

Trimetazidine in Application Value to Explore the Treatment of Coronary Heart Disease with Heart Failure

目的分析并研究曲美他嗪在冠心病合并心力衰竭患者治疗中的应用价值。方法选取2015年3月至2016年3月期间上饶市广丰区人民医院收治的冠心病合并心力衰竭患者86例,按照随机数字表抽取法均分成对照组和观察组,每组各43例,其中对照组患者采用常规疾病内科治疗方式,观察组在对照组治疗的基础上增加曲美他嗪治疗,观察比较两组患者的治疗效果及治疗前后左室舒张期末内径和左室收缩期末内径及左室射血分数。结果观察组患者治疗有效率为95.34%,对照组患者治疗有效率为81.40%,数据比较差异具有统计学意义(P<0.05);治疗后,观察组患者左室舒张期末内径、左室收缩期末内径显著低于对照组,左室射血分数显著高于对照组,数据比较差异具有统计学意义(P<0.05)。结论对冠心病合并心力衰竭患者在常规治疗的基础上增加曲美他嗪具有显著的效果,且安全性较高,具有重要的临床价值。

Objective To analysis and study of trimetazidine in the treatment of patients with coronary heart disease with heart failure.Methods In March 2015 to March 2016,select our hospital 86 cases of patients with coronary heart disease with heart failure,according to random number table extraction method were divided into control group and observation group,43 cases in each group,the control group were treated by routine medical treatment,disease on the basis of the observation group was treated in the control group increased trimetazidine treatment,compare two groups of patients before and after the treatment effect and treatment of left ventricular diastolic final inner diameter and left ventricular contraction the inner diameter and left ventricular ejection fraction.Results The observation group of patients treatment effective rate was 95.34%,control group patients treatment effective rate of 81.40%,data comparison differences statistically significant（P〈0.05）; After treatment,the observation group of patients with left ventricular inner diameter and left ventricular diastolic final shrinkage final diameter was significantly lower than control group,left ventricular ejection fraction was significantly higher than that of control group,data comparison differences statistically significant（P〈0.05）.Conclusion In patients with coronary heart disease with heart failure on the basis of conventional treatment increased trimetazidine has significant effect,and high security has important clinical value.